NEW YORK (GenomeWeb News) – Empire Genomics today announced it has received a Phase I SBIR grant from the National Cancer Institute to develop a genomic companion diagnostic test for multiple myeloma.

It is the first SBIR grant for Buffalo, NY-based Empire. The firm plans to use the funds to further develop its licensed technology for use in predicting multiple myeloma patient response to therapeutic treatments.

The grant lasts through October. According to the National Institutes of Health's grants database, the grant is for $142,432.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.